Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6268 | 1442 | 36.8 | 76% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CACO 2 | Author keyword | 33 | 16% | 13% | 193 |
2 | SINGLE PASS INTESTINAL PERFUSION | Author keyword | 13 | 62% | 1% | 13 |
3 | INTESTINAL PERFUSION | Author keyword | 12 | 35% | 2% | 29 |
4 | DRUG ABSORPTION | Author keyword | 11 | 19% | 4% | 53 |
5 | TALINOLOL | Author keyword | 10 | 40% | 1% | 20 |
6 | BIOPHARMACEUTICS CLASSIFICATION SYSTEM | Author keyword | 7 | 27% | 2% | 23 |
7 | ABSORPTIVE CLEARANCE | Author keyword | 6 | 80% | 0% | 4 |
8 | HUMAN INTESTINAL PERMEABILITY | Author keyword | 6 | 71% | 0% | 5 |
9 | BIOPHARMACEUTIC CLASSIFICATION SYSTEM | Author keyword | 5 | 63% | 0% | 5 |
10 | ORAL ABSORPTION | Author keyword | 5 | 10% | 3% | 42 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | DRUG ABSORPTION | 41 | 19% | 14% | 199 |
2 | PARTITION RELATIONSHIPS | 26 | 100% | 1% | 11 |
3 | SECRETORY TRANSPORT | 22 | 66% | 1% | 21 |
4 | LINE CACO 2 | 22 | 17% | 8% | 117 |
5 | SINGLE PASS PERFUSION | 18 | 83% | 1% | 10 |
6 | DEPENDENT ABSORPTION | 16 | 52% | 2% | 22 |
7 | TRUE HOMOLOGOUS SERIES | 15 | 82% | 1% | 9 |
8 | POLARIZED EFFLUX SYSTEM | 15 | 54% | 1% | 19 |
9 | USSING CHAMBER | 15 | 42% | 2% | 27 |
10 | REGIONAL JEJUNAL PERFUSION | 15 | 73% | 1% | 11 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics | 2005 | 324 | 106 | 45% |
Regional intestinal drug permeation: Biopharmaceutics and drug development | 2014 | 9 | 75 | 59% |
Caco-2 monolayers in experimental and theoretical predictions of drug transport | 2001 | 524 | 94 | 53% |
In situ perfusion in rodents to explore intestinal drug absorption: Challenges and opportunities | 2015 | 1 | 135 | 39% |
Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development | 2014 | 8 | 96 | 49% |
Variability in Caco-2 and MDCK cell-based intestinal permeability assays | 2008 | 57 | 91 | 69% |
In vitro models to evaluate the permeability of poorly soluble drug entities: Challenges and perspectives | 2012 | 29 | 128 | 47% |
The Caco-2 cell monolayer: usefulness and limitations | 2008 | 70 | 123 | 50% |
Permeability for Intestinal Absorption: Caco-2 Assay and Related Issues | 2008 | 60 | 58 | 53% |
Caco-2 monolayers in experimental and theoretical predictions of drug transport | 2012 | 20 | 96 | 53% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | GRP BIOPHARMACEUT | 4 | 75% | 0.2% | 3 |
2 | PRECLIN DRUG METAB PHARMACOKINET | 4 | 26% | 0.8% | 12 |
3 | PRECLIN CANDIDATE SELECT UNIT | 3 | 60% | 0.2% | 3 |
4 | GUT BARRIER GRP | 2 | 36% | 0.3% | 5 |
5 | BIOCHEM ENVIRONM CARCINOGENS BIU | 2 | 67% | 0.1% | 2 |
6 | DMPK SAFETY | 2 | 67% | 0.1% | 2 |
7 | DRUG DEV PHARMACOKINET PLICAT CRO | 2 | 67% | 0.1% | 2 |
8 | LEBENSMITTELTOXIKOL | 2 | 67% | 0.1% | 2 |
9 | PREFORMULAT SCI | 2 | 67% | 0.1% | 2 |
10 | BIOPHARMACEUT GRP | 2 | 27% | 0.5% | 7 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000176069 | HUMAN INTESTINAL ABSORPTION//PAMPA//LOG BB |
2 | 0.0000169767 | DISSOLUTION TECHNOLOGIES//BIORELEVANT MEDIA//BIOWAIVER |
3 | 0.0000166783 | PEPT1//PEPT2//HPEPT1 |
4 | 0.0000139792 | INO 2628 CZ//DOUBLE PEAKS//DISCONTINUOUS ABSORPTION |
5 | 0.0000103453 | SODIUM CAPRATE//SUPPOSITORY//ABSORPTION ENHANCER |
6 | 0.0000093301 | PROXIMITY ORIENTATION//CYCLIC PRODRUG//ESTERASE SENSITIVE PRODRUGS |
7 | 0.0000090870 | CYP3A//COCKTAIL//MECHANISM BASED INHIBITION |
8 | 0.0000081202 | SEDDS//SMEDDS//SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM |
9 | 0.0000080853 | P GLYCOPROTEIN//C3435T POLYMORPHISM//ABCB1 |
10 | 0.0000079375 | OATP1B1//SLCO1B1//OATP |